Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2

• Published in: Biomedicines 2023-01, Vol.11 (1), p.160
• Main Authors: Wey, Leoni, Masetto, Thomas, Spaeth, Alexander, Brehm, Jessica, Kochem, Christian, Reinhart, Marco, Müller, Holger, Kempin, Uwe, Lorenz, Franziska, Peter, Christoph, Grimmler, Matthias
• Format: Article
• Language: English
• Subjects: Amino acids; Antibodies; Antigens; Coronaviruses; COVID-19; COVID-19 vaccines; Cross-reactivity; Disease transmission; Enzymes; Genomes; Immunoassay; Immunoreactivity; Infections; Mutation; N protein; Nucleocapsids; Pandemics; Performance evaluation; PETIA; Pneumonia; Proteins; Public health; RNA polymerase; S-RBD; SARS-CoV-2; Serology; Severe acute respiratory syndrome coronavirus 2; Viruses; VOC
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11010160

Since SARS-CoV-2 emerged in December 2019 in Wuhan, the resulting pandemic has paralyzed the economic and cultural life of the world. Variants of concern (VOC) strongly increase pressure on public health systems. Rapid, easy-to-use, and cost-effective assays are essential to manage the pandemic. Here we present a bioinformatical approach for the fast and efficient design of two innovative serological Particle Enhanced Turbidimetric Immunoassays (PETIA) to quantify the SARS-CoV-2 immunoresponse. To confirm bioinformatical assumptions, an S-RBD- and a Nucleocapsid-based PETIA were produced. Sensitivity and specificity were compared for 95 patient samples using a BioMajesty™ fully automated analyzer. The S-RBD-based PETIA showed necessary specificity (98%) over the N protein-based PETIA (21%). Further, the reactivity and cross-reactivity of the RBD-based PETIA towards variant-derived antibodies of SARS-CoV-2 were assessed by a quenching inhibition test. The inhibition kinetics of the S-RBD variants , , , , , and were evaluated. In summary, we showed that specific and robust PETIA immunoassays can be rapidly designed and developed. The quantification of the SARS-CoV-2-related immunoresponse of variants ( to ) is possible using specific RBD assays. In contrast, revealed lower cross-reactivity (approx. 50%). To ensure the quantification of the variant, modified immunoassays appear to be necessary.